arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Bicara Therapeutics Inc.

BCAX

$8.17 ▼ -0.73 (-8.20%) at close

15 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Bicara Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $555.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -12.8% ↘

FCF / Share $-0.65 ↘

Trailing P/E —

Price / Book 1.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-56.21M

↓ -52.6% —

FCF / Share Free cash flow per share

$-0.65

↓ -5.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	-64.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-36.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	58.1% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	97.4% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	96.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	95.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-52.6% Weak ↑ Weak Improving Year-over-year change in net income	-52.6% Weak ↑ Weak Improving Year-over-year change in net income	-78.4% Weak ↑ Weak Improving Year-over-year change in net income	-194.6% Weak ↓ Weak Declining Year-over-year change in net income	-194.6% Weak ↓ Weak Declining Year-over-year change in net income	-194.6% Weak ↓ Weak Declining Year-over-year change in net income	-68.5% Weak Weak Year-over-year change in net income	-68.8% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	—	-19.9% Weak Weak Year-over-year change in free cash flow	—	—	—	97.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Effective Tax Rate (%) (%)	-0.1% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	—	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.43x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	—	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-12.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	11.3% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	9.6% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	9.2% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	7.0% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-11.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-3.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-5.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-12.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-180%)	-10.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-173%)	-9.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	-9.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-161%)	-8.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-156%)	-8.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-154%)	-4.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	-2.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-116%)	7.2% Caution → Caution Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-52%)	7.8% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-48%)	8.4% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-44%)	5.4% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-64%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-96.60M	$-323.46M	$-96.69M	$-171.67M	$-436.61M	$-462.06M	$-489.71M	$-520.76M	—	—	$-230.44M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.82	$-0.93	$-0.68	$-0.67	$-0.50	$-0.68	$7.22	$-1.60	$-19.01	$-18.94	$-19.43	$-38.23	—	—	—
Free Cash Flow per Share (USD)	$-0.65	$-0.62	—	$-0.54	—	$-0.52	—	—	$-14.42	$-22.10	—	—	—	—	—
Book Value per Share (USD)	$7.11	$7.84	$7.09	$7.38	$7.98	$8.42	$9.04	$9.37	$-194.90	$-242.44	$-232.31	$-229.44	—	—	—
Tangible Book Value per Share (USD)	$7.11	$7.84	$7.09	$7.38	$7.98	$8.42	$9.04	$9.37	$-194.90	$-242.44	$-232.31	$-229.44	—	—	—
Basic Weighted Avg Shares (shares)	67.93M	60.72M	—	54.56M	54.54M	54.46M	—	10.90M	896,744	660,288	—	597,586	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$460.35M	$505.57M	$393.10M	$276.34M	$427.16M	$451.63M	$484.54M	$507.03M	—	—	$215.99M	—	—	—	—
Total Equity (USD)	$468.77M	$513.96M	$401.45M	$402.78M	$435.20M	$458.96M	$491.88M	$509.56M	$-174.78M	$-160.08M	$-148.77M	$-137.11M	$-114.82M	$-105.91M	$-98.80M

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$44.00K	$44.00K	$43.00K	$24.00K	—	$19.00K	$15.00K	—	$13.00K	$13.00K	$14.00K	—	—	—	—
Net Income, GAAP (USD)	$-56.21M	$-56.21M	$-37.39M	$-36.85M	$-36.85M	$-36.85M	$-20.96M	$-12.51M	$-12.51M	$-12.51M	$-12.44M	$-7.41M	—	—	—
Operating Cash Flow (USD)	$-44.21M	$-37.51M	$-23.89M	$-29.25M	—	$-28.11M	$-30.03M	—	$-12.91M	$-14.59M	$-8.04M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 4 years · 15 quarters

Bicara Therapeutics Inc.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BCAX with peers